Teva launches generic version of Glaxo's migraine med Imitrex in U.S.

• Teva Pharmaceutical Industries (NYSE:TEVA -0.8%) launches its generic equivalent of GlaxoSmithKline's (GSK) Imitrex (sumatriptan succinate) in the U.S. for the treatment of acute migraine, with or without aura, and acute cluster headaches in adults.
• The product is self-administered via a prefilled syringe autoinjector developed by Antares Pharma (ATRS +15.4%).
• Per IMS data, sumatriptan injection sales in the U.S. are ~$183M a year.